化工社化工社 化学情報印刷レポート · 研究参考用
rac-(R*)-2-[[4-[[(2,4-ジアミノプテリジン-6-イル)メチル](メチル)アミノ]ベンゾイル]アミノ]ペンタン二酸
dl-メチルアミノプテリン · N-[4-[[(2,4-ジアミノプテリジン-6-イル)メチル](メチル)アミノ]ベンゾイル]-DL-グルタミン酸 · rac-(R*)-2-[[4-[[(2,4-ジアミノプテリジン-6-イル)メチル](メチル)アミノ]ベンゾイル]アミノ]ペンタン二酸 · rac-(R*)-2-[p-[[(2,4-ジアミノプテリジン-6-イル)メチル]メチルアミノ]ベンゾイルアミノ]ペンタン二酸 · dl-アメトプテリン · (±)-アメトプテリン · dl-メトトレキサート · (±)-N-[4-[[(2,4-ジアミノプテリジン-6-イル)メチル](メチル)アミノ]ベンゾイル]グルタミン酸
アミノ]ベンゾイル]アミノ]ペンタン二酸 の分子構造式](/img/chemical/4112.png)
識別子と物理属性
| CAS No. | 51865-79-3 |
|---|---|
| 分子式 | C20H22N8O5 |
| 平均分子量 | 454.4 g/mol |
| 単同位体質量 | 454.1713158 g/mol |
| SMILES | CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1 |
| InChIKey | FBOZXECLQNJBKD-UHFFFAOYSA-N |
| PubChem CID | 4112 |
| ChEMBL | CHEMBL426 |
| ChEBI | CHEBI:93775 |
| EC No. | 262-213-7 |
| DTXSID | DTXSID40859034 |
| 現地名 | rac-(R*)-2-[[4-[[(2,4-ジアミノプテリジン-6-イル)メチル](メチル)アミノ]ベンゾイル]アミノ]ペンタン二酸 |
化学・物理的性質
| XLogP | -1.8 |
|---|---|
| 極性表面積 | 211 |
| 水素結合供与体数 | 5 |
| 水素結合受容体数 | 12 |
| 回転可能結合数 | 9 |
| 重原子数 | 33 |
| 形式電荷 | 0 |
| 複雑度 | 704 |
| 医薬品 | Pharmaceuticals |
| 融点 | 195 °C (dec.)(lit.) |
| 密度 | 1.536±0.06 g/cm3(Predicted) |
| 貯蔵条件 | −20°C |
| 溶解度 | H2O: 最小量の 0.1M NaOH を加えて溶解し、中性緩衝液または生理食塩水で希釈します。希釈したストック溶液は、-20°C で 1 週間冷蔵保存すると安定です。不溶性 |
| pKa（酸解離定数） | 3.47±0.10(Predicted) |
| 外観・状態 | 粉 |
| 色 | 黄色 |
化学的特性
yellow to orange crystalline powder
安全性と法規制
| GHS 分類 | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P203, P264, P264+P265, P270, P280, P301+P316, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Treatment | Administer charcoal as a slurry. Consider gastric lavage after ingestion of a potentially life-threatening amount of poison if it can be performed soon after ingestion (generally within 1 hour). Protect airway by placement in Trendelenburg and left lateral decubitus position or by endotracheal intubation. Control any seizures first. Glucarpidase has been used intravenously in combination with thymidine and leucovorin to treat methotrexate toxicity. (T36) |
| 健康影響 | A small percentage of patients develop hepatitis, and there is an increased risk of pulmonary fibrosis where dry cough can be an important sign. The higher doses of methotrexate often used in cancer chemotherapy can cause toxic effects to the rapidly-dividing cells of bone marrow and gastrointestinal mucosa. The resulting myelosuppression and mucositis are often prevented (termed Leucovorin "rescue"- as this is the folic acid based drug used) (L1079). |
| 暴露経路 | Inhalation (A314)dermal (A314)intravenous (A314) Oral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect. |
| 毒性の概要 | Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known. |
| Signs and Symptoms | Symptoms of overdose include bone marrow suppression and gastrointestinal toxicity. |
| Carcinogen Classification | 3, not classifiable as to its carcinogenicity to humans. (L135) |
| Toxicity Data | LD50: 43 mg/kg (Oral, Rat) (A308) |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | MA1224100 |
| 輸送番号（UN） | UN 1544 6.1/PG 2 |
| 危険文句（R） | 61-25-36/38-23/24/25 |
| 危険表示 | T |
| 安全措置（S） | 53-26-36/37-45-36/37/39 |
用途
使用
Amethopterin is an antineoplastic, antirheumatic, folic acid antagonist